会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
    • 桥环碳氧酶丙型肝炎病毒丝氨酸蛋白酶抑制剂
    • WO2009085978A1
    • 2009-07-09
    • PCT/US2008087470
    • 2008-12-18
    • ENANTA PHARCEUTICALS INCLIU DONGOR YAT SUNWANG ZHE
    • LIU DONGOR YAT SUNWANG ZHE
    • A01N33/24A61K31/15
    • C07D273/00
    • The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit, and the oxime is tethered to one of the carboxylic acid on P2. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    • 本发明公开了式I化合物或其药学上可接受的盐,酯或前药:其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。 因此,本发明化合物干扰丙型肝炎病毒的生命周期,并且也可用作抗病毒剂。 更具体地说,本发明涉及含有碳环P2单元的肟化合物,肟与P2上的一个羧酸连接。 本发明进一步涉及包含前述化合物的药物组合物,用于给予患有HCV感染的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。